Related references
Note: Only part of the references are listed.The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials
I-Ling Cheng et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Antimicrobial-associated harm in critical care: a narrative review
Nishkantha Arulkumaran et al.
INTENSIVE CARE MEDICINE (2020)
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications
Alberto Enrico Maraolo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection A systematic review and network meta-analysis
Xinmei Tan et al.
MEDICINE (2020)
Evaluation of In Vitro Activity of Ceftolozane-tazobactam and Ceftazidime-avibactam Against Carbapenemase-producing Multi-drug Resistant Klebsiella pneumoniae Isolates
Huseyin Agah Terzi et al.
MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS (2020)
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
Keith S. Kaye et al.
CLINICAL INFECTIOUS DISEASES (2019)
The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection
Soichi Arakawa et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2019)
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis
Chi Phuong Nguyen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by US Census Divisions: Results from the 2017 INFORM Program
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials
Myra W. Popejoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)
Michael A. Pfaller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli
Yu Bin Seo et al.
BMC INFECTIOUS DISEASES (2017)
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)
Helio S. Sader et al.
JOURNAL OF INFECTION (2014)
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem
Carl Llor et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Candida Urinary Tract Infections-Epidemiology
Jack D. Sobel et al.
CLINICAL INFECTIOUS DISEASES (2011)
Executive Summary: International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
Kalpana Gupta et al.
CLINICAL INFECTIOUS DISEASES (2011)
Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria
Ann Pallett et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Vancomycin-Resistant Enterococcal Urinary Tract Infections
Brett H. Heintz et al.
PHARMACOTHERAPY (2010)
Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis
Florian M. E. Wagenlehner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics
Katsumi Shigemura et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2009)
Complicated urinary tract infections
Durwood E. Neal
UROLOGIC CLINICS OF NORTH AMERICA (2008)
Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults
LE Nicolle et al.
CLINICAL INFECTIOUS DISEASES (2005)
In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections
FME Wagenlehner et al.
CHEMOTHERAPY (2005)
New drugs for Gram-positive uropathogens
FME Wagenlehner et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Ertapenem - A review of its use in the management of bacterial infections
MP Curran et al.
DRUGS (2003)
Share Paper
